MedPage Today The final results of TAO, which failed to show an advantage for the investigational agent otamixaban versus unfractionated heparin with or without eptifibatide (Integrilin) in patients with non-ST-segment elevation acute coronary syndromes who were ...
PhysBizTech Those products in question are marked as “sodium chloride flush” and “ heparin lock flush,” an Aug. 19 Covidien news release stated. While a portion of the affected syringes may bear mismatched caps, labels and fluid volumes, most will not present any ... and more »
